Atlas Trials

A Study of MRG002 in the Treatment of Patients With HER2-positive Advanced Solid Tumors

Clinical trial NCT04941339 · UNKNOWN

Trial details

NCT number
NCT04941339
Sponsor
Shanghai Miracogen Inc.
Status
UNKNOWN
Phase
Phase 1
Study type
INTERVENTIONAL
Advanced Solid Tumor
Start date
2018-11-21
Primary completion
2022-10-01
Enrollment
74

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.